Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer.

Authors
  • Richards, Donald A
  • Loesch, David
  • Vukelja, Svetislava J
  • Wu, Hillary
  • Hyman, William J
  • Nieves, Jeffery
  • Wang, Yunfei
  • Hu, Simin
  • Shonukan, Oluwatoyin O
  • Tai, Datchen F
Type
Published Article
Journal
Investigational New Drugs
Publisher
Springer-Verlag
Publication Date
Oct 01, 2011
Volume
29
Issue
5
Pages
963–970
Identifiers
DOI: 10.1007/s10637-010-9414-6
PMID: 20352294
Source
Medline
License
Unknown

Abstract

Pemetrexed plus PLD was reasonably tolerated in this heavily-pretreated population. MTD: pemetrexed 500 mg/m(2) and PLD 40 mg/m(2) may be carried forward to phase II studies in specific patient populations. TTP in platinum-refractory ovarian patients was greater than expected.

Report this publication

Statistics

Seen <100 times